By Assoc. Prof. Dr. Mehmet Sorar | Published: 05.02.2025
Parkinson and TMS Treatment: Neuromodulation Support
In Parkinson's disease, transcranial magnetic stimulation (TMS) is an investigational option rather than a standard treatment. A European expert guideline rated high-frequency repetitive TMS as probably effective (Level B) for motor impairment and for depression in Parkinson's disease. US regulators have not cleared TMS for the disease. Its abstract does not address freezing of gait, tremor or the course of the disease.
What does the guideline say about Parkinson's disease and TMS?
The 2020 guideline by Lefaucheur and colleagues gave Level B, meaning probable efficacy, to high-frequency repetitive TMS in Parkinson's disease. The abstract names two targets: the motor cortex on both sides, or the left prefrontal cortex, for motor impairment or depression. Level A, meaning definite efficacy, went to only three other uses: neuropathic pain, depression and hand recovery after stroke.
The levels rest on differences between real and sham (fake) stimulation that were repeated across enough independent studies. The abstract gives no effect sizes, and the authors caution that a benefit supported by statistics does not automatically matter in daily life. It says nothing about slowing the course of the disease. The guideline covers literature to the end of 2018, so later studies are not included.
Which Parkinson symptoms does the evidence cover?
Only two aims are named in the guideline. The table shows what its abstract covers and what it leaves out:
| Symptom or aim | What the guideline abstract says |
|---|---|
| Motor impairment | Level B for high-frequency stimulation. The abstract does not give the size or length of benefit. |
| Depression in Parkinson's disease | Level B in the same guideline. |
| Freezing of gait, tremor, balance, speech | Not named. Ask for the study behind any claim. |
| Slowing or stopping the disease | Not addressed. |
| Thinking problems or dementia in Parkinson's disease | Not named. Ask for the study behind any claim. |
Accounts of "less freezing" or "steadier steps" after TMS are personal impressions. Groups given sham stimulation also report improvement, which is why the page on TMS sessions and what they involve explains that a felt change does not show what the stimulation did. The Cleveland Clinic lists Parkinson's disease among the conditions under study but not cleared by the US Food and Drug Administration (FDA), and the 2022 FDA timeline by Cohen and colleagues does not list it among the cleared uses.
How does TMS differ from deep brain stimulation in Parkinson's disease?
TMS and deep brain stimulation (DBS) are different kinds of treatment with different evidence, and the Cleveland Clinic lists implanted brain stimulators as a reason not to give TMS. The comparison is:
| Aspect | TMS | DBS |
|---|---|---|
| How it is given | A coil on the head. No surgery or sedation (Cleveland Clinic). | An implanted brain stimulator. |
| Position in Parkinson's disease | Not FDA-cleared. Level B for motor impairment or depression. | Described as established for advanced Parkinson's disease in the 2022 systematic review by Artusi and colleagues. |
| Having both | Implanted brain stimulators are listed as a reason not to give TMS (Cleveland Clinic). The Oxford Health leaflet lists deep brain stimulators too. | Not described. |
Anyone who already has a DBS system should therefore not assume that TMS is an option. How DBS is used, and for whom, is covered on the page about deep brain stimulation in Parkinson's disease.
What about Parkinson Plus syndromes?
For Parkinson Plus conditions, the evidence is thinner still. A 2021 review by Petsani and colleagues covered progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy and Lewy body disease. It says these conditions have no disease-modifying treatments (treatments that change the course of the disease), so care is mainly symptomatic. Most of the repetitive TMS studies reviewed reported benefit for motor and non-motor symptoms, but the authors call the evidence preliminary and note that large double-blind trials are missing. The guideline by Lefaucheur and colleagues does not list any of these conditions at Level A or B.
DBS is not supported either. Artusi and colleagues reviewed 25 studies covering 66 people and concluded that current evidence does not support DBS in atypical parkinsonism, which is the term used for these conditions. The separate page on TMS in Parkinson Plus conditions goes through these findings.
What side effects occur, and which implants rule TMS out?
Headache, scalp discomfort and mild facial twitching are the side effects the Cleveland Clinic names as common. It calls seizure the most serious and very rare. Figures differ between sources, so no single rate can be quoted, and they are compared on the page about TMS safety data.
The Cleveland Clinic and the Oxford leaflet list these reasons not to give TMS, or to take particular care:
- Implanted brain stimulators, including deep brain stimulators.
- Other metal or electronic implants fixed in the head or neck, for example cochlear implants, aneurysm clips or coils, metal plates or shrapnel.
- A pacemaker or defibrillator (the Oxford leaflet notes the manufacturer's advice against use with a pacemaker).
- Epilepsy or earlier seizures. People with epilepsy are not usually treated by the Oxford service, and the Cleveland Clinic says a seizure history raises the risk.
Which questions fit Parkinson's disease specifically?
Asking which symptom is the target and which evidence level applies is the most direct check. You can ask:
- Is the aim to improve movement or to treat depression?
- Which region will be stimulated, and how often? The protocols in the guideline are high-frequency.
- Do I have a DBS system or another metal or electronic implant, and how does that affect suitability?
- Could my medicines raise the seizure risk?
- Which studies support "probable efficacy" for my symptoms, and what size and length of benefit did they find?
- How and when will progress be measured, and what happens if there is no benefit?
What should you report if you try TMS alongside Parkinson's care?
If a seizure or loss of consciousness happens away from the clinic, get emergency help. Contact the treating team promptly about a headache that keeps worsening or any new implant. In detail:
- A seizure during or after a session, even one that stopped by itself.
- A headache that simple painkillers do not relieve or that is getting worse.
- A new implant, including a stimulator, or a new medicine.
- Low mood that appears or worsens, or thoughts of harming yourself. Seek medical help at once.
Do not change Parkinson's medicines on your own. Any change belongs with the doctor who prescribes them. The general explanation of TMS, its forms and its clearances is on the page that sets out how TMS therapy is applied and what is known in Parkinson's disease.
Sources
- Lefaucheur et al.: Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018), Clinical Neurophysiology 2020
- Cleveland Clinic: Transcranial Magnetic Stimulation (TMS)
- Cohen et al.: A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices, Brain Stimulation 2022
- Artusi et al.: Deep brain stimulation for atypical parkinsonism: A systematic review on efficacy and safety, Parkinsonism & Related Disorders 2022
- Petsani et al.: Therapeutic Application of rTMS in Atypical Parkinsonian Disorders, Behavioural Neurology 2021
- Oxford Health NHS Foundation Trust: rTMS patient information leaflet (v7.0, 2026)
This article is for general information and does not replace medical diagnosis or treatment. Please consult your physician for advice about your own condition.
Assoc. Prof. Dr. Mehmet Sorar
Neurosurgeon in Ankara. Graduated from Gazi University Faculty of Medicine in 1997, specialist since 2004, associate professor since 2019. Full CV
Related treatment page: TMS Tedavisi